5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | NEUTRAL | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 6.95▼ | 6.91▲ | 6.86▲ | 7.41▼ | 6.57▲ |
MA10 | 6.92▲ | 6.81▲ | 6.86▲ | 7.56▼ | 6.60▲ |
MA20 | 6.84▲ | 6.89▲ | 7.11▼ | 6.71▲ | 6.72▲ |
MA50 | 6.89▲ | 7.32▼ | 7.62▼ | 6.51▲ | 8.70▼ |
MA100 | 7.23▼ | 7.68▼ | 7.00▼ | 6.63▲ | N/A |
MA200 | 7.61▼ | 6.82▲ | 6.70▲ | 8.08▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.023▲ | 0.047▲ | 0.003▲ | 0.040▲ | 0.232▲ |
RSI | 55.962▲ | 44.133▼ | 37.882▼ | 51.450▲ | 48.544▼ |
STOCH | 86.041▲ | 76.783 | 45.053 | 58.077 | 50.275 |
WILL %R | -10.526▲ | -13.514▲ | -51.880 | -54.515 | -42.448 |
CCI | 67.638 | 83.833 | 3.175 | -17.116 | 86.199 |
Wednesday, June 11, 2025 06:00 AM
PARIS, France, June 11, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company ...
|
Thursday, June 05, 2025 04:59 PM
Abivax Announces Results of its June 6, 2025 Annual General Meeting PARIS, France, June 11, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX ...
|
Thursday, June 05, 2025 12:59 PM
Explore the NASDAQ:ABVX financials. Find the Abivax ADR financial statements for a comprehensive overview of the company’s financial health. This summary highlights critical numbers from key ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
13/06/25 | 6.85 | 7.025 | 6.58 | 6.98 | 496,860 |
12/06/25 | 7.64 | 7.64 | 6.925 | 7.02 | 97,905 |
11/06/25 | 7.67 | 7.73 | 7.20 | 7.42 | 94,747 |
10/06/25 | 7.85 | 7.90 | 7.605 | 7.845 | 179,771 |
09/06/25 | 8.30 | 8.31 | 7.595 | 7.80 | 217,744 |
06/06/25 | 8.35 | 8.5744 | 8.15 | 8.19 | 121,539 |
05/06/25 | 8.00 | 8.2466 | 7.88 | 8.15 | 249,294 |
04/06/25 | 8.20 | 8.61 | 7.8922 | 8.06 | 394,897 |
03/06/25 | 6.50 | 7.8792 | 6.44 | 7.74 | 608,656 |
02/06/25 | 6.14 | 6.47 | 6.14 | 6.35 | 289,943 |
|
|
||||
|
|
||||
|
|